Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:27:37.950Z.
Calculation as of: 2026-10-06T18:27:37.950Z.
Quote observation: 2026-10-06T18:25:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48a0ac2e06a305f3cd7951aab0857df1d764d6a3c57040a498ae406f98205111
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-11-28.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NewAmsterdam Pharma Company N.V.
Market Cap
$2.52B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.57B
EV/EBITDA Ratio
N/A
TTM Avg
70.45x
3Y Avg
91.30x
5Y Avg
141.66x
Market Cap
$2.45B
EV/EBITDA Ratio
N/A
TTM Avg
43.52x
3Y Avg
24.79x
5Y Avg
21.77x
Market Cap
$2.40B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.40B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.65B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.66B
EV/EBITDA Ratio
32.57x
TTM Avg
28.10x
3Y Avg
22.56x
5Y Avg
30.37x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.52B | N/A | N/A | N/A | N/A |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | N/A | 70.45x | 91.30x | 141.66x |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | N/A | 43.52x | 24.79x | 21.77x |
| Beam Therapeutics Inc. (BEAM)vs › | $2.62B | N/A | N/A | N/A | N/A |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | N/A | N/A | N/A | N/A |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.65B | N/A | N/A | N/A | N/A |
| Neogen Corporation (NEOG)vs › | $2.66B | 32.57x | 28.10x | 22.56x | 30.37x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 13.13x | 11.53x | 20.03x | 19.21x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2022-11-28 | 2.99x |
| 2022-11-25 | 3.70x |
| 2022-11-23 | 4.01x |
| 2022-11-22 | 3.63x |
| 2022-11-21 | 3.49x |
| 2022-11-18 | 3.86x |
| 2022-11-17 | 3.57x |
| 2022-11-16 | 3.44x |
| 2022-11-15 | 3.88x |
| 2022-11-14 | 3.82x |
| 2022-11-11 | 3.58x |
| 2022-11-10 | 3.49x |
| 2022-11-09 | 3.24x |
| 2022-11-08 | 3.79x |
| 2022-11-07 | 3.79x |
| 2022-11-04 | 3.77x |
| 2022-11-03 | 3.77x |
| 2022-11-02 | 3.76x |
| 2022-11-01 | 3.77x |
| 2022-10-31 | 3.75x |
| 2022-10-28 | 3.76x |
| 2022-10-27 | 3.75x |
| 2022-10-26 | 3.75x |
| 2022-10-25 | 3.75x |
| 2022-10-24 | 3.74x |
| 2022-10-21 | 3.74x |
| 2022-10-20 | 3.74x |
| 2022-10-19 | 3.74x |
| 2022-10-18 | 3.72x |
| 2022-10-17 | 3.73x |
| 2022-10-14 | 3.72x |
| 2022-10-13 | 3.72x |
| 2022-10-12 | 3.71x |
| 2022-10-11 | 3.71x |
| 2022-10-10 | 3.71x |
| 2022-10-07 | 3.71x |
| 2022-10-06 | 3.71x |
| 2022-10-05 | 3.71x |
| 2022-10-04 | 3.71x |
| 2022-10-03 | 3.69x |
| 2022-09-30 | 3.71x |
| 2022-09-29 | 3.70x |
| 2022-09-28 | 3.69x |
| 2022-09-27 | 3.68x |
| 2022-09-26 | 3.68x |
| 2022-09-23 | 3.69x |
| 2022-09-22 | 3.69x |
| 2022-09-21 | 3.69x |
| 2022-09-20 | 3.69x |
| 2022-09-19 | 3.69x |
| 2022-09-16 | 3.71x |
| 2022-09-15 | 3.70x |
| 2022-09-14 | 3.70x |
| 2022-09-13 | 3.70x |
| 2022-09-12 | 3.70x |
| 2022-09-09 | 3.69x |
| 2022-09-08 | 3.69x |
| 2022-09-07 | 3.70x |
| 2022-09-06 | 3.70x |
| 2022-09-02 | 3.70x |
| 2022-09-01 | 3.69x |
| 2022-08-31 | 3.69x |
| 2022-08-30 | 3.68x |
| 2022-08-29 | 3.69x |
| 2022-08-26 | 3.68x |
| 2022-08-25 | 3.68x |
| 2022-08-24 | 3.68x |
| 2022-08-23 | 3.68x |
| 2022-08-22 | 3.68x |
| 2022-08-19 | 3.68x |
| 2022-08-18 | 3.67x |
| 2022-08-17 | 3.68x |
| 2022-08-16 | 3.67x |
| 2022-08-15 | 3.67x |
| 2022-08-12 | 3.67x |
| 2022-08-11 | 3.67x |
| 2022-08-10 | 3.67x |
| 2022-08-09 | 3.66x |
| 2022-08-08 | 3.68x |
| 2022-08-05 | 3.66x |
| 2022-08-04 | 3.67x |
| 2022-08-03 | 3.67x |
| 2022-08-02 | 3.66x |
| 2022-08-01 | 3.66x |
| 2022-07-29 | 3.66x |
| 2022-07-28 | 3.67x |
| 2022-07-27 | 3.66x |
| 2022-07-26 | 3.66x |
| 2022-07-25 | 3.66x |
| 2022-07-22 | 3.65x |
| 2022-07-21 | 3.65x |
| 2022-07-20 | 3.64x |
| 2022-07-19 | 3.65x |
| 2022-07-18 | 3.64x |
| 2022-07-15 | 3.63x |
| 2022-07-14 | 3.63x |
| 2022-07-13 | 3.63x |
| 2022-07-12 | 3.63x |
| 2022-07-11 | 3.63x |
| 2022-07-08 | 3.63x |
| 2022-07-07 | 3.64x |
| 2022-07-06 | 3.64x |
| 2022-07-05 | 3.64x |
| 2022-07-01 | 3.64x |
